Silk Road Medical Revenue and Competitors

Claim your profile

Location

$460.6M

Total Funding

Estimated Revenue & Valuation

  • Silk Road Medical's estimated annual revenue is currently $94.3M per year.(i)
  • Silk Road Medical received $47.0M in venture funding in July 2017.
  • Silk Road Medical's estimated revenue per employee is $236,441
  • Silk Road Medical's total funding is $460.6M.
  • Silk Road Medical's current valuation is $1.3B. (January 2022)

Employee Data

  • Silk Road Medical has 399 Employees.(i)
  • Silk Road Medical grew their employee count by 13% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.6M78-4%N/AN/A
#2
$3.5M34-8%N/AN/A
#3
$5.5M2283%N/AN/A
#4
$3.3M320%N/AN/A
#5
$5.8M23-28%N/AN/A
#6
$49.7M198-13%N/AN/A
#7
$9.8M39N/AN/AN/A
#8
$2.9M2875%N/AN/A
#9
$27.4M10911%N/AN/A
#10
$49.3M15728%$199.1MN/A

Silk Road Medical, Inc. is a privately held company located in Sunnyvale, California, dedicated to preventing the devastating burden of stroke through surgical innovation. The company develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies. By innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with carotid artery disease. Our history is one of deep collaboration with vascular specialists and our future will be guided by continuous learning, observation and improvement. For more information on the company, visit our website at http://silkroadmed.com/. The TransCarotid Artery Revascularization (TCAR) Procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE® Transcarotid Neuroprotection and Stent System are the first and only products specifically designed and indicated for TCAR in high surgical risk patients that need carotid intervention. For more information about the TCAR procedure and essential prescribing information, please visit http://silkroadmed.com/ifus/. For more information about carotid artery disease and the risks involved with any intervention (e.g. bleeding, death, myocardial infarction, restenosis, stroke, TIA, vessel dissection, vessel occlusion, etc.), please visit http://silkroadmed.com/disease-and-treatment-options/.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$460.6M

Total Funding

399

Number of Employees

$94.3M

Revenue (est)

13%

Employee Growth %

$1.3B

Valuation

N/A

Accelerator

Silk Road Medical News

2022-04-19 - Should You Buy Silk Road Medical Inc (SILK) Stock After it Is Down 16.04% in a Week?

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new...

2022-04-19 - Analysts Anticipate Silk Road Medical, Inc (NASDAQ:SILK ...

Analysts Anticipate Silk Road Medical, Inc (NASDAQ:SILK) Will Announce Earnings of -$0.41 Per Share. Posted by admin on Apr 23rd, 2022.

2022-04-06 - Silk Road Medical - What A Road It Has Been

Silk Medical Road is a medtech business which focuses on the development of devices which both reduce the risk and the impact of a stroke. The...

2019-09-08 - Silk Road Medical Announces Closing of Follow-on Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Silk Road Medical Announces Closing of Follow-on Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$73.6M4069%N/A
#2
$140.3M408-1%N/A
#3
$692.4M4193%N/A
#4
$153M4224%N/A
#5
$75.8M4334%N/A

Silk Road Medical Funding

DateAmountRoundLead InvestorsReference
2014-08-15$15.0MUndisclosedArticle
2015-10-21$57.0MUndisclosedCRGArticle
2017-07-19$47.0MUndisclosedJanus CapitalArticle